Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPGDP Regimen in ENKL
NCT02560441Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Sep 2015
- Primary completion
- Sep 2022
- Modality
- Therapeutic Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of ifosfamide, pegaspargase, gemcitabine, cisplatin, dexamethasone in Extranodal NK/T-cell lymphoma nasal type (ENKTCL-NT), sponsored by Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
ifosfamidepegaspargasegemcitabinecisplatindexamethasone
03
Conditions
Extranodal NK/T-cell lymphoma nasal type (ENKTCL-NT)
Beyond the preview
Go deeper on NCT02560441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02560441.